Brookline Capital Markets Reiterates Intellia Therapeutics (NTLA) at Buy, Estimates NTLA-5001 Peak Sales of $2.6B
Tweet Send to a Friend
Brookline Capital Markets analyst Leah RUsh Cann reiterated a Buy rating and $91.00 price target on Intellia Therapeutics (NASDAQ: NTLA) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
